TY - JOUR
TI - Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations
AU - Baliakas, P.
AU - Agathangelidis, A.
AU - Hadzidimitriou, A.
AU - Sutton, L.-A.
AU - Minga, E.
AU - Tsanousa, A.
AU - Scarfò, L.
AU - Davis, Z.
AU - Yan, X.-J.
AU - Shanafelt, T.
AU - Plevova, K.
AU - Sandberg, Y.
AU - Vojdeman, F.J.
AU - Boudjogra, M.
AU - Tzenou, T.
AU - Chatzouli, M.
AU - Chu, C.C.
AU - Veronese, S.
AU - Gardiner, A.
AU - Mansouri, L.
AU - Smedby, K.E.
AU - Pedersen, L.B.
AU - Moreno, D.
AU - Van Lom, K.
AU - Giudicelli, V.
AU - Francova, H.S.
AU - Nguyen-Khac, F.
AU - Panagiotidis, P.
AU - Juliusson, G.
AU - Angelis, L.
AU - Anagnostopoulos, A.
AU - Lefranc, M.-P.
AU - Facco, M.
AU - Trentin, L.
AU - Catherwood, M.
AU - Montillo, M.
AU - Geisler, C.H.
AU - Langerak, A.W.
AU - Pospisilova, S.
AU - Chiorazzi, N.
AU - Oscier, D.
AU - Jelinek, D.F.
AU - Darzentas, N.
AU - Belessi, C.
AU - Davi, F.
AU - Ghia, P.
AU - Rosenquist, R.
AU - Stamatopoulos, K.
JO - Blood advances
PY - 2015
VL - 125
TODO - 5
SP - 856-859
PB - American Society of Hematology
SN - null
TODO - 10.1182/blood-2014-09-600874
TODO - adult;  adult;  amino acid composition;  amino acid composition;  Article;  cancer patient;  cancer patient;  cancer prognosis;  cancer prognosis;  chronic lymphatic leukemia;  chronic lymphatic leukemia;  female;  female;  gene mutation;  gene mutation;  human;  human;  IGHV3 21 gene;  IGHV3 21 gene;  in situ hybridization;  in situ hybridization;  major clinical study;  major clinical study;  male;  male;  priority journal;  priority journal;  prospective study;  prospective study;  tumor gene;  tumor gene;  aged;  B lymphocyte;  drug effects;  gene expression regulation;  gene rearrangement;  genetic heterogeneity;  genetics;  immunology;  Leukemia, Lymphocytic, Chronic, B-Cell;  middle aged;  mortality;  pathology;  prognosis;  somatic hypermutation;  survival analysis;  time to treatment;  treatment outcome, antineoplastic agent;  immunoglobulin heavy chain, Aged;  Antineoplastic Agents;  B-Lymphocytes;  Female;  Gene Expression Regulation, Leukemic;  Gene Rearrangement, B-Lymphocyte, Heavy Chain;  Genetic Heterogeneity;  Humans;  Immunoglobulin Heavy Chains;  Leukemia, Lymphocytic, Chronic, B-Cell;  Male;  Middle Aged;  Prognosis;  Somatic Hypermutation, Immunoglobulin;  Survival Analysis;  Time-to-Treatment;  Treatment Outcome
TODO - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL. © 2015 by The American Society of Hematology 10.1182/blood-2014-09-600874.
ER -